Cell-based assay demonstrates broad activity against viral proteases in various CoVs, suggesting potential for screening drug candidates.
Cell-based fluorescent assay with high sensitivity and low background that reports on the activity of viral proteases, which are key drug targets. Assay is compatible with not only theSARS-CoV-2 Mproprotein but also orthologues from a range of human and nonhuman CoVs as well as clinically reportedSARS-CoV-2 drug-resistant Mprovariants. The assay is run using Cell-based (293T) Panel of transfected CoV proteases. 2 𝜇M of a P-gp inhibitor is also used. Candidate perturbagens are screened as part of the assay The assay is run as a panel to define the breadth of activity against of viral proteases and results reported against this set
No takes yet. Share an insight, caveat, or question.
Nick Lynch (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: